Last reviewed · How we verify
NCT06795438
Effects of Green Tea on Cardiometabolic Outcomes
NA trial testing Green tea in Cardiometabolic Syndrome in 40 participants. Not yet recruiting.
1 February 2027
Quick facts
| Lead sponsor | University of Central Lancashire |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 1 April 2025 |
| Primary completion | 1 February 2027 |
| Estimated completion | 1 June 2027 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Green tea — full drug profile →
- Placebo
Conditions studied
- Cardiometabolic Syndrome — all drugs for Cardiometabolic Syndrome →
Sponsor
University of Central Lancashire
Who can join
Adults 18 to 65, any sex, with Cardiometabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Green tea may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06795438
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Green tea
Trials testing the same drug.
- NCT07002307 — The Effect of Honey-sweetened Coffee, Black Tea and Green Tea on Some Physiological Parameters · NA · completed
- NCT05222425 — Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3 · Phase 3 · unknown
- NCT05181176 — Effect of Coffee and Tea Consumption on Adolescent Weight Control · NA · unknown
- NCT04543422 — Green Tea Extracts for Mild-to-moderate Diabetic Peripheral Neuropathy · NA · completed
- NCT03537625 — Effects of Green Tea on Body Weight Reduction and Gut Microbiota · NA · completed
Other recruiting trials for Cardiometabolic Syndrome
Currently open trials in the same condition.
- NCT06865885 — LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering · Phase 4 · recruiting
- NCT06645691 — Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body · Phase 2 · recruiting
- NCT06784154 — The Role of Ectopic Fat and Heart Attack Risk in HIV · recruiting
- NCT06277661 — The Mom and Infant Outcomes (MOMI) Study · NA · recruiting
- NCT06538714 — Interval Training and Cardio-metabolic Health in Overweight/Obese Girls · NA · recruiting
Other University of Central Lancashire trials
Trials by the same sponsor.
- NCT07350473 — Effects of Vibration-Assisted Physical Activity in Type-2 Diabetes · NA · not yet recruiting
- NCT07296068 — Can Acute Photobiomodulation Improve Balance and Cognition in Individuals With Ataxia: a Pilot Feasibility Placebo Rando · NA · not yet recruiting
- NCT06901986 — Health Benefits of Tart Cherry in Crohn's Disease · NA · not yet recruiting
- NCT07260903 — Can Photobiomodulation Improve Balance and Cognition in Individuals Over 60: a Pilot Feasibility Placebo Randomized Cont · NA · recruiting
- NCT06559982 — Effects of a Brown Seaweed Tart Cherry Blend in Mild-moderate Hypertension · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06795438 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Central Lancashire
- Last refreshed: 27 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06795438.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing